It was a great pleasure to speak with Stephen Pasternak (University of Western Ontario, Ontario, Canada) to discuss the phase 2 trial investigating ambroxol as a disease-modifying treatment for Parkinson’s Disease dementia.
The abstract entitled ‘Ambroxol as a Disease-modifying Treatment for Parkinson’s Disease Dementia: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial’ was presented at The 15th International Conference for Alzheimer’s & Parkinson’s Diseases (Virtual), March 8-14, 2021.
Questions:
- What were the inclusion criteria and outcome measures of the Phase 2 study? (0:14)
- What were the efficacy and safety findings of the study? (2:33)
- What is the clinical significance of these findings and what future studies are planned? (4:35)
Disclosures: Stephen Pasternak received consulting fees from Zywie Bio LLC.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AD/PD Virtual 2021.
